Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership positions in its U.S. business following executive orders by President Donald Trump to stop diversity,

With its Q1 2025 results on Wednesday, Novo Nordisk (NVO) lowered its full-year outlook, but its shares were rising in European trading after the pharma giant projected a sales recovery for its blockbuster weight loss therapy Wegovy in the months ahead.

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions